Rossari Biotech Q1 Review - Building Product Pipeline To Drive The Business Growth: KRChoksey

BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..KRChoksey Research Report.Rossari Biotech Ltd. consolidate revenue grew by 88% YoY at Rs 4,347 million (5% below our estimates) which includes mergers’ impact and can’t be compared directly with Q1 FY22; however, it has observed decline by 1% QoQ in revenue. Standalone revenue reported at Rs 2,337 million (up 14.6% YoY / 10.7% down QoQ). Rossari Biotech's Ebitda reported at Rs 577 million (up 52% YoY / up 10% QoQ; 5% above our estimates); as Ebitda margin reported at 13.3% (down 310 bps YoY / up 136.3 bps QoQ) on account of price increases and softening of raw material prices (above our estimates of 12.0%). Profit after tax reported at Rs 286.81 (17% YoY/ 19% QoQ) as against Rs 240.8 million in Q4 FY22..Click on the attachment to read the full report:.DISCLAIMERThis report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Rossari Biotech Q1 Review - Building Product Pipeline To Drive The Business Growth: KRChoksey

Rossari Biotech Q1 Review - Building Product Pipeline To Drive The Business Growth: KRChoksey

Choose a plan